RADIANCE: A Randomized Controlled Study of Ranibizumab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia

Wolf, Sebastian; Balčiūnienė, Vilma Jūratė; Laganovska, Guna; Menchini, Ugo; Ohno‐Matsui, Kyoko; Sharma, Tarun; Wong, Tien Yin; Silva, Rufino; Pilz, Stefan; Gekkieva, Margarita

doi:10.1016/j.ophtha.2013.10.023

Cited by 284 publications

(327 citation statements)

References 40 publications

Supporting

Mentioning

289

Contrasting

Unclassified

Order By: Relevance

“…Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) is the current treatment of choice for mCNV patients and OCT was indicated in the RADIANCE and MYRROR studies, both multicenter randomized controlled Phase III trials for the monitoring of disease activity after treatment 95,96 (Figure 8). When a treated lesion shows cessation of activity, the lesion becomes more compact, the internal reflectivity is often less than the surface, the boundary between the lesion and retina is sharp, and there is no associated intra-or subretinal fluid.…”

Section: Myopic Choroidal Neovascularizationmentioning

confidence: 99%

Advances of optical coherence tomography in myopia and pathologic myopia

Cheung

Luk

et al. 2016

Eye

View full text Add to dashboard Cite

show abstract

Section: Myopic Choroidal Neovascularizationmentioning

confidence: 99%

Advances of optical coherence tomography in myopia and pathologic myopia

Cheung

Luk

et al. 2016

Eye

View full text Add to dashboard Cite

show abstract

“…25 More recent clinical trials have, however, demonstrated that anti-VEGF therapy achieves much better visual outcomes for myopic CNV than vPDT therapy. [26][27][28] Anti-VEGF therapy is currently the standard of care for treating myopic CNV. 29 vPDT therapy has been used as a treatment for other causes of CNV with variable outcomes.…”

Section: Vpdt Treatment Protocolsmentioning

confidence: 99%

Photodynamic therapy: current role in the treatment of chorioretinal conditions

Newman

2016

Eye

View full text Add to dashboard Cite

Verteporfin photodynamic therapy (vPDT) is a selective vaso-occlusive treatment that targets choroidal vascular abnormalities. It was initially developed to treat neovascular age-related macular degeneration using the 'standard' vPDT protocol (verteporfin 6 mg/ m 2 , vPDT laser fluence 50 J/cm 2 ). vPDT therapy has subsequently evolved as an important treatment modality for a range of other chorioretinal conditions including choroidal haemangioma, central serous chorioretinopathy, polypoidal choroidal vasculopathy, and peripapillary choroidal neovascularisation. Various 'safety-enhanced' vPDT protocols have been devised to optimise treatment outcomes, typically using reduced dose verteporfin (verteporfin 3 mg/m 2 ) or reduced fluence vPDT (vPDT laser fluence 25 J/cm 2 ). This paper reviews the current role of vPDT therapy in the treatment of chorioretinal conditions.

show abstract

“…Einzelne Fallserien zeigen jedoch ähnli-che Behandlungsraten (Median: 2 im ersten Jahr) unter PRN (pro re nata) [123], wie sie unter dem Protokoll der RADIANCE-Studie für Ranibizumab beschrieben wurden [162]. Immerhin gibt es auch eine randomisierte Studie, die die Wirksamkeit von Bevacizumab und Ranibizumab verglichen hat [124].…”

Section: Zentrale Netzhaut Und Myope Choroidale Neovaskularisationunclassified